Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Richtlijnen voor moleculaire beeldvorming van de borsten voor borstbiopten bij patiënten met borstafwijkingen

30 september 2026 bijgewerkt door: Mayo Clinic

Klinische pilotstudie ter evaluatie van moleculaire beeldvorming van de borsten - Leidraad voor het nemen van monsters van borstafwijkingen

This clinical trial tests how well molecular breast imaging (MBI) works to guide the collection of a breast biopsy in patients with a breast abnormality. Currently, a biopsy is often guided by either ultrasound or mammography in order to ensure that a sample of the correct part of the breast is taken. Sometimes a lesion or part of the lesion cannot be seen on ultrasound or mammography, and, therefore, a biopsy guided with ultrasound or mammography may not be always be accurate. Studies have shown that high resolution MBI may have potential to improve the detection of some breast tumors. This trial uses a new high-resolution MBI system that may help perform a biopsy using MBI.

Studie Overzicht

Gedetailleerde beschrijving

PRIMARY OBJECTIVE:

I. To evaluate a methodology for MBI-guided biopsy of suspicious breast lesions.

OUTLINE: Patients are assigned to 1 of 2 study parts.

PART I: Patients receive technetium Tc-99m sestamibi intravenously (IV) and undergo MBI on study.

PART II: Patients receive technetium Tc-99m sestamibi IV and undergo MBI. Patients whose breast lesions of interest are visualized on MBI then undergo breast biopsy using the Stereo Navigator accessory.

After completion of study intervention, patients may be asked to follow up at 3-6 months.

Studietype

Ingrijpend

Inschrijving (Geschat)

70

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Minnesota
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Werving
        • Mayo Clinic in Rochester
        • Contact:
        • Hoofdonderzoeker:
          • Katie N. Hunt, M.D.

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • PART I: Women aged 18 years or older

  • PART I: If able to become pregnant, negative pregnancy test within 48 hours prior to MBI biopsy procedure

  • PART I: Individuals who have previously (within the last 3 years) undergo an MBI study and were found to have at least one breast imaging finding on MBI that was subsequently shown (through additional imaging, biopsy or follow-up) to be benign in nature

  • PART I: Individuals who have agreed to participate in the study and who have signed the study-specific informed consent

  • PART II: Women aged 18 years or older

  • PART II: If able to become pregnant, negative pregnancy test within 48 hours prior to MBI biopsy procedure

  • PART II: Individuals who have previously (within the last 3 years) undergone an MBI study and were found to have at least one breast imaging finding on MBI that was subsequently shown (through additional imaging, biopsy or follow-up) to be benign or probably benign in nature

  • PART II: Individuals who had recent conventional imaging work-up including either x-ray mammography, ultrasound, MBI, or MRI of the breast and are found to have at least one breast imaging finding for which biopsy is required or recommended, specifically:

    • Individuals who have a breast abnormality(ies) on imaging with mammography, ultrasound, MBI, or MRI (as per American College of Radiology [ACR] Breast Imaging Reporting and Data System [BIRADS] 3, or higher) and requiring imaging follow-up or biopsy confirmation
  • PART II: Individuals who have agreed to participate in the study and who have signed study-specific informed consent

Exclusion Criteria:

  • PART I: Women who are pregnant
  • PART I: Women who are currently lactating or discontinued breastfeeding < 2 months prior to the study
  • PART I: Age less than 18 years
  • PART I: Women with breast implant(s) in the breast containing the lesion of interest
  • PART I: Inability to provide informed consent
  • PART II: Women who are pregnant
  • PART II: Women who are currently lactating or discontinued breastfeeding < 2 months prior to the study
  • PART II: Age less than 18 years
  • PART II: Women with breast implant(s) in the breast containing the lesion of interest
  • PART II: Women who have recently (within the last 3 months) undergone biopsy of the breast finding
  • PART II: Women who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of MBI-guided biopsy
  • PART II: Patients with contraindications for core biopsy and other invasive procedures such as blood coagulation disorders, infection, or who are unwilling to discontinue use of anticoagulant medication prior to the procedure
  • PART II: Inability to provide informed consent
  • PART II: Women who have had surgery on the study breast(s) within the past 12 months

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Diagnostisch
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Part I (technetium Tc-99m sestamibi, MBI)

Patients receive technetium Tc-99m sestamibi IV and undergo MBI on study.

Undergo MBI

Andere namen:
  • MBI
  • Borstspecifieke Gamma-beeldvorming
  • Miraluma-scan
  • Miraluma-test
  • Moleculaire beeldvorming van de borst
  • Nucleaire Geneeskunde Borstbeeldvorming
  • sestamibi borst beeldvorming
  • Sestamibi scintimammografie

Given IV

Andere namen:
  • Cardioliet
  • Miraluma
  • Tc 99m Sestamibi
  • Tc-99m MIBI
  • Tc99m Sestamibi
  • Technetium (99mTc) Sestamibi
  • 99mTc-methoxyisobutylisonitril
Experimenteel: Part II (technetium Tc-99m sestamibi, MBI, biopsy)

Patients receive technetium Tc-99m sestamibi IV and undergo MBI. Patients whose breast lesions of interest are visualized on MBI then undergo breast biopsy using the Stereo Navigator accessory.

Undergo MBI

Andere namen:
  • MBI
  • Borstspecifieke Gamma-beeldvorming
  • Miraluma-scan
  • Miraluma-test
  • Moleculaire beeldvorming van de borst
  • Nucleaire Geneeskunde Borstbeeldvorming
  • sestamibi borst beeldvorming
  • Sestamibi scintimammografie

Given IV

Andere namen:
  • Cardioliet
  • Miraluma
  • Tc 99m Sestamibi
  • Tc-99m MIBI
  • Tc99m Sestamibi
  • Technetium (99mTc) Sestamibi
  • 99mTc-methoxyisobutylisonitril

Undergo biopsy of breast

Andere namen:
  • Biopsie van de borst

Utilization of the Stereo Navigator accessory

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Validation of timeframe
Tijdsspanne: Baseline

Time from injection of the technetium Tc-99m sestamibi to identification of the appropriate needle guide hole will be reviewed to determine if and where any improvements in workflow can be made to reduce the overall procedure time for patients.

Baseline
Change in image of lesion
Tijdsspanne: Baseline; Up to 6 months

The coordinates of the lesion of interest on the high resolution MBI image will be recorded. The guidance procedure will be considered successful if 1) the pre and post images of the lesion demonstrated one of the following: decreased in size, central or eccentric defect where sampled, or decrease in intensity, or 2) pathology results demonstrate malignancy or a specific benign concordant result.

Baseline; Up to 6 months
Accuracy of depth estimation by difference in attenuation from opposing views
Tijdsspanne: Baseline; Up to 6 months

For each patient in whom pathology confirms successful sampling of the lesion seen on high-resolution molecular breast imaging (MBI), the error in depth estimation will be calculated as the average error for each depth estimation method from all core biopsy samples. This will allow comparison of the accuracy of the 3 different depth estimation methods and potentially provide further information on the strengths and weakness of each of the three methods for depth estimation. Uniformity activity along the entire 20 mm core would indicate failure to biopsy the lesion. Any portion of increased uptake will be noted and the center of activity will be determined relative to the mid-point of the core sample. This distance will be recorded as the difference between estimated depth and true depth.

Baseline; Up to 6 months
Accuracy of depth estimation by difference in apparent lesion size
Tijdsspanne: Baseline; Up to 6 months

For each patient in whom pathology confirms successful sampling of the lesion seen on MBI, the error in depth estimation will be calculated as the average error for each depth estimation method from all core biopsy samples. This will allow comparison of the accuracy of the 3 different depth estimation methods and potentially provide further information on the strengths and weakness of each of the three methods for depth estimation. Uniformity activity along the entire 20 mm core would indicate failure to biopsy the lesion. Any portion of increased uptake will be noted and the center of activity will be determined relative to the mid-point of the core sample. This distance will be recorded as the difference between estimated depth and true depth.

Baseline; Up to 6 months
Accuracy of depth estimation by triangulation
Tijdsspanne: Baseline; Up to 6 months

For each patient in whom pathology confirms successful sampling of the lesion seen on MBI, the error in depth estimation will be calculated as the average error for each depth estimation method from all core biopsy samples. This will allow comparison of the accuracy of the 3 different depth estimation methods and potentially provide further information on the strengths and weakness of each of the three methods for depth estimation. Uniformity activity along the entire 20 mm core would indicate failure to biopsy the lesion. Any portion of increased uptake will be noted and the center of activity will be determined relative to the mid-point of the core sample. This distance will be recorded as the difference between estimated depth and true depth.

Baseline; Up to 6 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Hoofdonderzoeker: Katie N. Hunt, M.D., Mayo Clinic in Rochester

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

26 augustus 2021

Primaire voltooiing (Geschat)

31 december 2027

Studie voltooiing (Geschat)

31 december 2027

Studieregistratiedata

Eerst ingediend

13 september 2023

Eerst ingediend dat voldeed aan de QC-criteria

22 september 2023

Eerst geplaatst (Werkelijk)

28 september 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

30 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 18-011329
  • 18-011329 (Andere identificatie: Mayo Clinic in Rochester)
  • NCI-2023-06047 (Register-ID: CTRP (Clinical Trial Reporting Program))

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren